Digesting the doughnut hole.

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Geriatric Medicine

Background:

• Medicare Part D, a prescription drug benefit program, faces criticism for its coverage gap, known as the "doughnut hole."
• The impact of this coverage gap on medication adherence and healthcare utilization among beneficiaries, particularly those with chronic conditions like diabetes, remains a key area of study.

Purpose of the Study:

• To investigate the effect of the Medicare Part D coverage gap on prescription drug utilization patterns among seniors with diabetes.
• To compare drug usage between beneficiaries in the coverage gap and those not exposed to it.

Main Methods:

• Comparative analysis of prescription drug use among Medicare Part D beneficiaries.
• Stratification of drug use based on medication cost, type (brand-name vs. generic), and therapeutic class.

Main Results:

• The coverage gap was found to disrupt prescription drug use in seniors with diabetes, with modest declines observed.
• Higher-cost, brand-name medications, including antipsychotics, antiasthmatics, and central nervous system drugs, saw usage declines of 8-18%.
• Lower-cost medications with high generic availability, such as beta blockers, ACE inhibitors, and antidepressants, experienced smaller declines of 3-5% in the coverage gap.

Conclusions:

• The Medicare Part D doughnut hole impacts prescription drug adherence, particularly for more expensive medications.
• Despite reduced adherence, the study found no associated increase in medical service utilization, suggesting limited downstream healthcare cost implications from the gap itself.